Airway inflammation and eotaxin in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy

Advances in Medical Sciences

Volumn 56, Issue 2, 2011, Pages 318-322

  Zietkowski, Z ^a   Skiepko, R ^a   Tomasiak Lozowska, M M ^a   Bodzenta Lukaszyk, A ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

airway inflammation; asthma; eotaxin; exhaled breath condensate; omalizumab

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; EOSINOPHIL CATIONIC PROTEIN; EOTAXIN; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING BETA 2 AGONIST; NITRIC OXIDE; OMALIZUMAB; SHORT ACTING BETA 2 AGONIST; STEROID; UNCLASSIFIED DRUG;

ADULT; AIRWAY INFLAMMATION; ALLERGIC ASTHMA; ARTICLE; BLOOD EOSINOPHIL COUNT; BLOOD SAMPLING; BREATHING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; EOSINOPHIL COUNT; EOSINOPHILIA; EXHALATION; EXHALED BREATH CONDENSATE; FEMALE; HUMAN; INFLAMMATION; MALE; RESPIRATORY TRACT DISEASE; RISK FACTOR; SEVERE PERSISTENT ALLERGIC ASTHMA; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHEMOKINE CCL11; EOSINOPHILS; EXHALATION; FEMALE; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; INFLAMMATION; MALE; MIDDLE AGED; NITRIC OXIDE; TIME FACTORS;

EID: 83155171940     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.2478/v10039-011-0024-0     Document Type: Article

References (26)

1. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Effcacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy. 2004 Jul;59(7):701-8. (Pubitemid 38850344)
2. Gonlugur U, Efeoglu T. Vascular adhesion and transendothelial migration of eosinophil leukocytes. Cell Tissue Res. 2004 Dec;318(3):473-82. (Pubitemid 40109937)
3. Tai PC, Sun L, Spry CJ. Effects of IL-5, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosinophils in vitro. Clin Exp Immunol. 1991 Aug;85(2):312-6.
4. Miotto D, Christodoulopoulos P, Olivenstein R, Taha R, Cameron L, Tsicopoulos A, Tonnel AB, Fahy O, Laftte JJ, Luster AD, Wallaert B, Mapp CE, Hamid Q. Expression of IFN-gamma-inducible protein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in TH1-and TH2-mediated lung diseases. J Allergy Clin Immunol. 2001 Apr;107(4):664-70. (Pubitemid 32397755)
5. Luster AD. Chemokines-chemotactic cytokines that mediate infammation. N Engl J Med. 1998 Feb 12;338(7):436-45. (Pubitemid 28135672)
6. Platts-Mills TA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 2):S1-5. (Pubitemid 33116525)
7. Global Initiative for Asthma. Global strategy for asthma management and prevention: NHLBI/WHO Report 2006; Publication 02-3569.
8. Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, Deniz Y. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical effcacy in the treatment of allergic asthma. Curr Med Res Opin. 2003;19(6):491-8. (Pubitemid 37122042)
9. American Thoracic Society/American Lung Association. Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-1999. This offcial statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 1999 Dec;160(6):2104-17.
10. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis. 1991 Nov;144(5):1202-18.
11. Horváth I, Hunt J, Barnes PJ, Alving K, Antczak A, Baraldi E, Becher G, van Beurden WJ, Corradi M, Dekhuijzen R, Dweik RA, Dwyer T, Effros R, Erzurum S, Gaston B, Gessner C, Greening A, Ho LP, Hohlfeld J, Jöbsis Q, Laskowski D, Loukides S, Marlin D, Montuschi P, Olin AC, Redington AE, Reinhold P, van Rensen EL, Rubinstein I, Silkoff P, Toren K, Vass G, Vogelberg C, Wirtz H; ATS/ERS Task Force on Exhaled Breath Condensate. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J. 2005 Sep;26(3):523-48. (Pubitemid 41264218)
12. Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2003 Feb;111(2 Suppl):S486-94. (Pubitemid 36223287)
13. Adamko DJ, Odemuyiwa SO, Vethanayagam D, Moqbel R. The rise of the phoenix: the expanding role of the eosinophil in health and disease. Allergy. 2005 Jan;60(1):13-22.
14. Hamelmann E. The rationale for treating allergic asthma with anti-IgE. Eur Respir Rev. 2007 Sept 1; 16(104): 61-6. (Pubitemid 350075091)
15. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefts of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005 Mar;60(3):309-16. (Pubitemid 40293346)
16. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, Fowler-Taylor A, Matthews J, Busse WW, Holgate ST, Fahy JV. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway infammation in allergic asthma. Am J Respir Crit Care Med. 2004 Sep 15;170(6):583-93.
17. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-infammatory effects of omalizumab confrm the central role of IgE in allergic infammation. J Allergy Clin Immunol. 2005 Mar;115(3):459-65. (Pubitemid 40341694)
18. Foroughi S, Foster B, Kim N, Bernardino LB, Scott LM, Hamilton RG, Metcalfe DD, Mannon PJ, Prussin C. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol. 2007 Sep;120(3):594-601. (Pubitemid 47320766)
19. Palframan RT, Collins PD, Williams TJ, Rankin SM. Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrow. Blood. 1998 Apr 1;91(7):2240-8. (Pubitemid 28155496)
20. Woo CH, Jeong DT, Yoon SB, Kim KS, Chung IY, Saeki T, Kim JH. Eotaxin induces migration of RBL-2H3 mast cells via a Rac-ERK-dependent pathway. Biochem Biophys Res Commun. 2002 Nov 1;298(3):392-7. (Pubitemid 35333718)
21. Uguccioni M, Mackay CR, Ochensberger B, Loetscher P, Rhis S, LaRosa GJ, Rao P, Ponath PD, Baggiolini M, Dahinden CA. High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. J Clin Invest. 1997 Sep 1;100(5):1137-43. (Pubitemid 27386297)
22. Miller CW, Krishnaswamy N, Johnston C, Krishnaswamy G. Severe asthma and the omalizumab option. Clin Mol Allergy. 2008 May 20;6:4.
23. Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Lenczewska D, Bodzenta-Lukaszyk A. RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy. Int Arch Allergy Immunol. 2011;154(1):25-32.
24. Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Bodzenta-Lukaszyk A. Anti-IgE therapy with omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthma. Respiration. 2010;80(6):534-42.
25. Mochizuki M, Bartels J, Mallet AI, Christophers E, Schröder JM. IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy. J Immunol. 1998 Jan 1;160(1):60-8. (Pubitemid 28116715)
26. Teran LM, Mochizuki M, Bartels J, Valencia EL, Nakajima T, Hirai K, Schröder JM. Th1-and Th2-type cytokines regulate the expression and production of eotaxin and RANTES by human lung fbroblasts. Am J Respir Cell Mol Biol. 1999 Apr;20(4):777-86. (Pubitemid 129495666)